Bone biology, signaling pathways, and therapeutic targets for osteoporosis

Nicole M. Iñiguez-Ariza, Bart L. Clarke

Research output: Contribution to journalReview articlepeer-review

38 Scopus citations


Major advances have occurred recently in the treatment of osteoporosis in recent years. Most patients are currently treated with bisphosphonates, denosumab, raloxifene, or teriparatide, and in some countries, strontium ranelate. Strontium ranelate and calcitonin have recently had their use restricted due to cardiovascular concerns and malignancy, respectively. The available agents have generally provided excellent options that effectively reduce fracture risk. New targets are being sought based on appreciation of the bone biology and signaling pathways involved in bone formation and resorption. These agents will directly target these signaling pathways, and further expand the options available for treatment of osteoporosis.

Original languageEnglish (US)
Pages (from-to)245-255
Number of pages11
Issue number2
StatePublished - Oct 1 2015


  • Anti-Dickkopf antibody
  • Anti-sclerostin antibody
  • Cathepsin K inhibitors
  • Osteoporosis
  • PTH
  • PTHrP

ASJC Scopus subject areas

  • General Biochemistry, Genetics and Molecular Biology
  • Obstetrics and Gynecology


Dive into the research topics of 'Bone biology, signaling pathways, and therapeutic targets for osteoporosis'. Together they form a unique fingerprint.

Cite this